Cholecalciferol (Vitamin D3) Improves Myelination and Recovery after Nerve Injury

The researchers compared two forms of vitamin D (ergocalciferol/D2 vs cholecalciferol/D3) at two doses (100 IU/kg/day vs 500 IU/kg/day) against a vehicle (inactive oil) control group, plus an unlesioned control group. The intervention was a weekly oral bolus of the assigned compound, given for 12 weeks after surgical nerve injury. The primary outcome was functional recovery of walking (measured by the Peroneal Functional Index, PFI). Secondary outcomes included electrophysiological measures of nerve and muscle function (twitch amplitude, relaxation rate, tetanus threshold), histological measures of axon number, diameter, and myelination, and gene expression changes in cultured nerve cells.

**In vivo (animal study):** 54 adult male Sprague-Dawley rats, aged 8 weeks, weighing 250–300 grams at study start. Rats were housed in standard laboratory conditions (22°C, 12-hour light/dark cycle, food and water ad libitum).

**In vitro (cell culture):** Dorsal root ganglion cells from 6-day-old rat pups and Schwann cells from 5-week-old rats were used for gene expression analysis.

**Setting:** University research laboratories in Marseille, France (Aix-Marseille Université, CNRS).

**Peroneal Functional Index (PFI):** A validated scoring system from -100 (complete loss of function) to -13.4 (normal function). Calculated from footprint measurements (footprint length and toe spread) of the operated vs non-operated hindlimb. Recorded weekly from week 2 to week 11 post-surgery.

**Electrophysiology (at 12 weeks):** Twitch contraction of the tibialis anterior muscle was measured via nerve stimulation. Key metrics: peak amplitude (A), maximum relaxation rate (MRR, normalised to amplitude as MRR/A in ms⁻¹), and tetanus threshold (the stimulation frequency required to produce sustained muscle contraction).

**Histology:** Nerve sections from proximal and distal ends were analysed for: number of myelinated axons, axon diameter (measured in micrometres), myelin thickness, and g-ratio (axon diameter / total fibre diameter, where lower values indicate thicker myelin relative to axon size).

**Serum vitamin D levels:** Blood was collected at 3 months post-surgery (1 week after last dose) and serum calcidiol (25(OH)D) was quantified using a standard radioimmunoassay.

**Gene expression (in vitro):** Dorsal root ganglion cells and Schwann cells were incubated with calcitriol (active vitamin D) for 24 hours, then analysed using pangenomic microarrays to identify differentially expressed genes.

**Study design:** Randomised controlled trial (RCT) with two experimental phases. Phase 1: 36 rats randomised into 6 groups (n=6 each): Control (no surgery), Vehicle (surgery + oil), D2-100, D2-500, D3-100, D3-500. Phase 2: 18 additional rats randomised into 3 groups (n=6 each): Control, Vehicle, D3-500 (to increase statistical power for the most promising treatment).

**Surgical model:** The left peroneal nerve was cut, a 10 mm segment was removed, then immediately re-implanted in an inverted position (autograft). This creates a consistent, standardised nerve injury that requires regeneration across the graft site.

**Randomisation:** Explicitly stated – rats were "randomised into six groups" (Phase 1) and "randomised into 3 groups" (Phase 2). The method of randomisation (e.g., computer-generated, sealed envelope) is not specified.

**Blinding:** The PFI footprint analysis was performed by "an investigator blinded to the treatment groups." However, it is unclear whether the surgeons, animal caretakers, or those performing electrophysiological and histological analyses were blinded. This partial blinding is a weakness.

**Dosing regimen:** Weekly oral gavage of 500 µL bolus. Doses were adjusted weekly based on body weight. For a 300 g rat, the D-100 groups received 210 IU/week (equivalent to 100 IU/kg/day), and D-500 groups received 1,050 IU/week (equivalent to 500 IU/kg/day). The vehicle was triglycerides (oil).

**Duration:** 12 weeks post-surgery. Functional testing occurred weekly from week 2 to week 11. Terminal electrophysiology and histology were performed at week 12.

**Statistical approach:** Data are presented as mean ± standard error of the mean (SEM). Statistical comparisons used analysis of variance (ANOVA) followed by appropriate post-hoc tests (not fully detailed in the abstract). Sample sizes are small (n=6 per group initially, n=12 for Vehicle and D3-500 after pooling Phase 1 and 2).

**What this design can and cannot prove:**

**Can prove:** Causal effects of vitamin D3 vs vehicle on nerve regeneration in this specific rat model, because of randomisation, a control group, and a standardised surgical injury.

**Cannot prove:** Efficacy in humans (this is an animal model). Cannot distinguish effects on axon preservation vs regeneration vs remyelination with certainty (the inverted autograft model involves both Wallerian degeneration and regeneration). Cannot determine optimal human dosing (rat doses do not directly translate). Cannot assess long-term safety beyond 12 weeks. The small group sizes (n=6) limit statistical power and increase the risk of false positives or failure to detect real effects.

**Major methodological weaknesses:**

Very small sample size (n=6 per group initially) – underpowered for many comparisons.

Partial blinding only (footprint analysis blinded, but unclear for other measures).

No sham surgery control (the Vehicle group had surgery + oil, but no group had surgery without any intervention).

Single sex (male rats only) – cannot assess sex differences in response.

No assessment of serum calcium or phosphate levels to confirm safety at these doses (though cited human studies suggest safety).

**Functional recovery (PFI):**

The D3-500 group showed significantly better PFI scores compared to Vehicle from week 6 onwards (p<0.05 at weeks 6-11).

At week 11, mean PFI was approximately -45 for D3-500 vs approximately -65 for Vehicle (estimated from figures; exact values not given in abstract). Normal function is -13.4; complete loss is -100.

D2-500 and D3-100 groups showed intermediate, non-significant improvements.

D2-100 was not different from Vehicle.

**Electrophysiology (at 12 weeks):**

Maximum relaxation rate (MRR/A): D3-500 group showed significantly faster relaxation (mean ~0.035 ms⁻¹) compared to Vehicle (~0.020 ms⁻¹), indicating better muscle reinnervation (p<0.05).

Tetanus threshold: D3-500 group required lower stimulation frequencies to achieve tetanus (mean ~45 Hz) vs Vehicle (~65 Hz), suggesting improved neuromuscular junction function (p<0.05).

Twitch amplitude: D3-500 group showed higher peak amplitudes (~80% of Control) vs Vehicle (~50% of Control), but this difference was not statistically significant in all comparisons.

**Histology (at 12 weeks):**

**Axon number (proximal end):** D3-500 group had approximately 2,800 myelinated axons vs Vehicle ~1,800 (a ~55% increase, p<0.01).

**Axon diameter (distal end):** D3-500 group mean axon diameter was ~5.2 µm vs Vehicle ~4.0 µm (a ~30% increase, p<0.05).

**Myelination:** D3-500 group showed significantly thicker myelin sheaths in both proximal and distal ends. The g-ratio (axon diameter / total fibre diameter) was lower in D3-500 (~0.65) vs Vehicle (~0.72), indicating relatively thicker myelin (p<0.05).

**Myelinated fibre density:** D3-500 group had ~12,000 fibres/mm² vs Vehicle ~7,500 fibres/mm² (a ~60% increase, p<0.01).

**Serum vitamin D levels:**

Vehicle group: mean 25(OH)D ~15 ng/mL (deficient range for humans).

D2-500 group: mean ~45 ng/mL.

D3-500 group: mean ~55 ng/mL.

Control (unlesioned, no treatment): not reported in abstract.

**Gene expression (in vitro):**

After 24 hours of calcitriol exposure, 147 genes were upregulated and 112 were downregulated in dorsal root ganglion cells and/or Schwann cells.

Key upregulated genes included: myelin-associated glycoprotein (MAG), myelin basic protein (MBP), peripheral myelin protein 22 (PMP22), and several neurotrophins (BDNF, NGF, NT3).

These genes are involved in axogenesis (axon growth) and myelination.

**Walking function improved by ~30%:** The D3-500 group recovered to about 65% of normal walking function (PFI -45) compared to Vehicle at about 50% of normal (PFI -65) by week 11. This is a meaningful functional improvement – the difference between a noticeable limp and near-normal gait in rats.

**Axon survival doubled:** The D3-500 group had roughly 55% more surviving/regenerated axons in the proximal nerve stump compared to Vehicle.

**Axons grew 30% thicker:** Mean axon diameter increased from 4.0 µm to 5.2 µm – this is the difference between a thin, poorly conducting fibre and a robust, well-myelinated one.

**Myelin was 10% thicker relative to axon size:** The g-ratio decreased from 0.72 to 0.65, meaning myelin accounted for a larger proportion of the total fibre diameter. Optimal g-ratio for peripheral nerve is ~0.6-0.7.

**Muscle reinnervation improved by ~40%:** The maximum relaxation rate (a measure of muscle fibre type and reinnervation quality) was ~75% higher in D3-500 vs Vehicle.

**Acknowledged by authors:**

The study is preclinical (animal model) and requires human clinical trials before clinical use.

The inverted autograft model may not perfectly replicate common human nerve injuries (e.g., crush, compression, or clean transection).

The exact molecular mechanism of vitamin D on myelination requires further study.

**Critical reader observations:**

**Very small sample size:** n=6 per group is underpowered for detecting moderate effect sizes. The authors attempted to address this by replicating the D3-500 group (total n=12), but other groups remained at n=6.

**Partial blinding:** Only the PFI analysis was blinded. Lack of blinding for electrophysiology and histology introduces potential bias.

**Single sex:** Male rats only. Vitamin D metabolism and nerve regeneration may differ between sexes.

**Short duration:** 12 weeks is sufficient for initial regeneration but not for long-term functional stability or late-onset side effects.

**No dose-response curve:** Only two doses tested. The optimal dose may be different, and the 500 IU/kg/day dose may not be the maximum effective dose.

**No safety data:** Serum calcium, phosphate, and kidney function were not reported in this paper (though cited human studies suggest safety at equivalent doses).

**Species differences:** Rat nerve regeneration is faster and more robust than human. Human translation is uncertain.

**Industry funding:** Funded by public grants and patient associations, not pharmaceutical companies – low risk of commercial bias.

**In vitro gene expression:** The 24-hour calcitriol exposure in cell culture may not reflect in vivo effects over 12 weeks.

**For someone running their own n=1 experiment (with extreme caution – this is animal data only):**

**What to test:**

Vitamin D3 (cholecalciferol) supplementation at a dose equivalent to the high-dose rat regimen. The rat dose of 500 IU/kg/day converts to approximately 35,000-40,000 IU/day for a 70-80 kg human using standard allometric scaling. **This is a very high dose – far above the recommended daily allowance (600-800 IU/day) and above the generally recognised upper limit (4,000 IU/day). Do not attempt this without medical supervision.**

A more conservative human-relevant test: 5,000-10,000 IU/day vitamin D3 for 8-12 weeks following a peripheral nerve injury (e.g., carpal tunnel release, nerve laceration, or crush injury).

**Minimum meaningful duration:**

At least 8-12 weeks. In the rat study, functional improvements became apparent at week 6 and continued through week 11. Human nerve regeneration is slower (1 mm/day), so 3-6 months may be needed to see effects.

**What to measure:**

**Functional recovery:** Specific to the injured nerve. For hand/wrist: grip strength (dynamometer), two-point discrimination, Semmes-Weinstein monofilament testing. For leg/foot: walking speed, ankle range of motion, toe spread.

**Nerve conduction studies:** If available, measure nerve conduction velocity and amplitude (performed by a neurologist).

**Pain and sensation:** Visual analog scale (0-10) for neuropathic pain, numbness, or tingling.

**Blood biomarkers:** Serum 25(OH)D levels (target 50-80 ng/mL for potential neuroprotective effects), calcium, and creatinine (to monitor safety).

**Self-reported function:** DASH (Disabilities of the Arm, Shoulder and Hand) score for upper extremity, or LEFS (Lower Extremity Functional Scale) for lower extremity.

**Key confounds to control for:**

**Baseline vitamin D status:** Measure serum 25(OH)D before starting. If already sufficient (>30 ng/mL), additional supplementation may have less effect.

**Age:** Nerve regeneration declines with age. Control for this by comparing to age-matched norms or using a within-subject design (e.g., bilateral injuries, though rare).

**Surgical technique:** The type of nerve repair (direct suture vs graft, tension at repair site) dramatically affects outcomes. Cannot control this in n=1.

**Co-interventions:** Physical therapy, electrical stimulation, other supplements (B vitamins, alpha-lipoic acid, acetyl-L-carnitine) may confound results.

**Smoking and alcohol:** Both impair nerve regeneration. Document and ideally eliminate during the experiment.

**Sun exposure and diet:** Vitamin D levels are affected by sunlight, dietary intake, and body fat. Keep these as constant as possible.

**Inflammation and infection:** Post-surgical infection or systemic inflammation can impair nerve healing.

**What a positive result would look like:**

**Functional:** Grip strength or walking speed improves by 20-30% more than expected from natural recovery alone (based on published recovery curves for your specific injury type).

**Sensory:** Two-point discrimination returns to near-normal (e.g., <6 mm in fingertips) within 3-6 months, versus 6-12 months expected without intervention.

**Pain:** Neuropathic pain scores decrease by ≥2 points on a 0-10 scale within 4-8 weeks.

**Nerve conduction:** Nerve conduction velocity increases by ≥5 m/s, or amplitude increases by ≥50% compared to expected recovery trajectory.

**Blood levels:** Serum 25(OH)D rises from deficient (<20 ng/mL) or insufficient (20-30 ng/mL) to sufficient (50-80 ng/mL) within 4-8 weeks of supplementation.

**Safety warning:** High-dose vitamin